Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) diary in patients with influenza-like illness (ILI)-Reference-Cited by-同舟云学术

Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) diary in patients with influenza-like illness (ILI)

Published:2018-03-22 Issue:3 Volume:13 Page:e0194180
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Powers John H.^ORCID,Bacci Elizabeth D.,Leidy Nancy K.,Poon Jiat-Ling,Stringer Sonja,Memoli Matthew J.,Han Alison,Fairchok Mary P.,Coles Christian,Owens Jackie,Chen Wei-Ju,Arnold John C.,Danaher Patrick J.,Lalani Tahaniyat,Burgess Timothy H.,Millar Eugene V.,Ridore Michelande,Hernández Andrés,Rodríguez-Zulueta Patricia,Ortega-Gallegos Hilda,Galindo-Fraga Arturo,Ruiz-Palacios Guillermo M.,Pett Sarah,Fischer William,Gillor Daniel,Moreno Macias Laura,DuVal Anna,Rothman Richard,Dugas Andrea,Guerrero M. Lourdes

Funder

National Institutes of Health

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference16 articles.

1. Centers for Disease Control and Prevention (CDC) (2016) Key Facts about Influenza (Flu) & Flu Vaccine.

2. Centers for Disease Control and Prevention (CDC) (2016) Overview of Influenza Surveillance in the United States.

3. What is sufficient evidence for the reliability and validity of patient-reported outcome measures?;MH Frost;Value in Health,2007

4. FDA draft guidance and health-outcomes research;DA Revicki;Lancet,2007

5. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report;M Rothman;Value Health,2009

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Uncovering a Severe Patient Group With Pollen-Related Extrarespiratory Allergic Symptoms: A Year-Long Diary Survey in Japan;The Journal of Allergy and Clinical Immunology: In Practice;2024-06

2. Coordinated nasal mucosa-mediated immunity accelerates recovery from COVID-19;ERJ Open Research;2024-02-20

3. The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus‐associated disease in breakthrough infections in adults ≥60 years of age;Influenza and Other Respiratory Viruses;2024-02

4. The Cost of Seasonal Influenza: A Systematic Literature Review on the Humanistic and Economic Burden of Influenza in Older (≥ 65 Years Old) Adults;Advances in Therapy;2024-01-23

5. Inhaled beclomethasone in the treatment of early COVID-19: a double-blind, placebo-controlled, randomised, hospital-based trial in Sri Lanka;BMJ Open;2023-12